{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:42:11Z","timestamp":1790484131398,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intravenous drug abuse (IDA) is a known risk factor for infective endocarditis (IE) and is associated with frequent relapses, but its prognostic impact is still debated. The potential futility of surgery in this population is a further issue under discussion. We aimed to describe the clinical characteristics, the therapeutic strategy, and the prognosis associated with IDA in IE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analysed 440 patients admitted to a single surgical centre for definite active IE from January 2012 to December 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients reporting IDA (N\u2009=\u200954; 12.2%) were significantly younger (p\u2009&lt;\u20090.001) and presented fewer comorbidities (p\u2009&lt;\u20090.001). IDA was associated with a higher proportion of relapses (27.8 vs. 3.3%, p\u2009&lt;\u20090.001) and, at multivariable analysis, was an independent predictor of long-term mortality (HR 2.3, 95%CI 1.1\u20134.7, p\u2009=\u20090.015). We did not register multiple relapses in non-IDA patients. Among IDA patients, we observed 1 relapse after discharge in 9 patients, 2 relapses in 5 patients and 3 relapses in 1 patient. In IDA patients, neither clinical and laboratory variables nor the occurrence of even multiple relapses emerged as indicators of an adverse risk\u2013benefit ratio of surgery in patients with surgical indication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IE secondary to IDA affects younger patients than those with IE not associated with IDA. Probably due to this difference, IE secondary to IDA is not associated with significantly higher mortality, whereas the negative, long-term prognostic impact of IDA emerges in multivariate analysis. Considering the good prognosis of patients with uncomplicated IE treated medically, surgery should be reserved to patients with a strict- guidelines-based indication. However, since there are no clear predictors of an unfavourable risk\u2013benefit ratio of surgery in patients with surgical indication, all patients with a complicated IE should be operated, irrespective of a history of IDA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06697-1","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T09:05:11Z","timestamp":1632733511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Infective endocarditis in intravenous drug abusers: clinical challenges emerging from a single-centre experience"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-7074","authenticated-orcid":false,"given":"Valentina","family":"Scheggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ceschia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Vanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Merilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Sottili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Salcuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zoppetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Alterini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Cerillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Stef\u00e0no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"5","key":"6697_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2018.10.082","volume":"73","author":"SE Rudasill","year":"2019","unstructured":"Rudasill SE, Sanaiha Y, Mardock AL, Khoury H, Xing H, Antonios JW, McKinnell JA, et al. Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol. 2019;73(5):559\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.082.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"6697_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/313664","volume":"30","author":"JA Frontera","year":"2000","unstructured":"Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000;30(2):374\u20139. https:\/\/doi.org\/10.1086\/313664.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6697_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/icvts\/ivz302","volume":"30","author":"V Rohn","year":"2020","unstructured":"Rohn V, Laca B, Horn M, Vlk L, Antonova P, Mosna F. Surgery in drug use-associated infective endocarditis: long-term survival is negatively affected by recurrence. Interact Cardiovasc Thorac Surg. 2020;30(4):528\u201334. https:\/\/doi.org\/10.1093\/icvts\/ivz302.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"3","key":"6697_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.athoracsur.2015.03.019","volume":"100","author":"NK Shrestha","year":"2015","unstructured":"Shrestha NK, Jue J, Hussain ST, Jerry JM, Pettersson GB, Menon V, et al. Injection drug use and outcomes after surgical intervention for infective endocarditis. Ann Thorac Surg. 2015;100(3):875\u201382. https:\/\/doi.org\/10.1016\/j.athoracsur.2015.03.019.","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"6697_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5220","volume":"1","author":"L Rodger","year":"2018","unstructured":"Rodger L, Glockler-Lauf SD, Shojaei E, Sherazi A, Hallam B, Koivu S, et al. Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open. 2018;1(7): e185220. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.5220.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6697_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.semtcvs.2018.07.016","volume":"31","author":"MJ Nguemeni Tiako","year":"2019","unstructured":"Nguemeni Tiako MJ, Mori M, Bin Mahmood SU, Shioda K, Mangi A, Yun J, et al. Recidivism is the leading cause of death among intravenous drug users who underwent cardiac surgery for infective endocarditis. Semin Thorac Cardiovasc Surg. 2019;31(1):40\u20135. https:\/\/doi.org\/10.1053\/j.semtcvs.2018.07.016.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"44","key":"6697_CR7","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"G Habib","year":"2015","unstructured":"Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, ESC Scientific Document Group, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075\u2013128. https:\/\/doi.org\/10.1093\/eurheartj\/ehv319.","journal-title":"Eur Heart J"},{"key":"6697_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejim.2020.04.017","volume":"78","author":"V Scheggi","year":"2020","unstructured":"Scheggi V, Alterini B, Olivotto I, Del Pace S, Zoppetti N, Tomberli B, et al. Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. Eur J Intern Med. 2020;78:82\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2020.04.017.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"6697_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12872-021-01991-x","volume":"21","author":"S Del Pace","year":"2021","unstructured":"Del Pace S, Scheggi V, Virgili G, Caciolli S, Olivotto I, Zoppetti N, et al. Endocarditis with spondylodiscitis: clinical characteristics and prognosis. BMC Cardiovasc Disord. 2021;21(1):186. https:\/\/doi.org\/10.1186\/s12872-021-01991-x.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"6697_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12872-021-01853-6","volume":"21","author":"V Scheggi","year":"2021","unstructured":"Scheggi V, Merilli I, Marcucci R, Del Pace S, Olivotto I, Zoppetti N, et al. Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. BMC Cardiovasc Disord. 2021;21(1):28. https:\/\/doi.org\/10.1186\/s12872-021-01853-6.","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"6697_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/ehjqcco\/qcz018","volume":"5","author":"G Habib","year":"2019","unstructured":"Habib G, Lancellotti P, Erba PA, Sadeghpour A, Meshaal M, Sambola A, EURO-ENDO Investigators, et al. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):202\u20137. https:\/\/doi.org\/10.1093\/ehjqcco\/qcz018.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"issue":"5","key":"6697_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jacc.2018.10.081","volume":"73","author":"G Habib","year":"2019","unstructured":"Habib G, Gouriet F, Casalta JP. Infective endocarditis in injection drug users: a recurrent disease. J Am Coll Cardiol. 2019;73(5):571\u20132. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.081.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"6697_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1749-8090-9-58","volume":"24","author":"A Weymann","year":"2014","unstructured":"Weymann A, Borst T, Popov AF, Sabashnikov A, Bowles C, Schmack B, et al. Surgical treatment of infective endocarditis in active intravenous drug users: a justified procedure? J Cardiothorac Surg. 2014;24(9):58. https:\/\/doi.org\/10.1186\/1749-8090-9-58.","journal-title":"J Cardiothorac Surg"},{"issue":"18","key":"6697_CR14","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2018.14071","volume":"320","author":"DP Serota","year":"2018","unstructured":"Serota DP, Wilson JD, Merlin JS. Injection drug use-associated infective endocarditis. JAMA. 2018;320(18):1939. https:\/\/doi.org\/10.1001\/jama.2018.14071.","journal-title":"JAMA"},{"issue":"4","key":"6697_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJMra1604339","volume":"375","author":"MA Schuckit","year":"2016","unstructured":"Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357\u201368. https:\/\/doi.org\/10.1056\/NEJMra1604339.","journal-title":"N Engl J Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06697-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T09:05:53Z","timestamp":1632733553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06697-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6697"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06697-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (Comitato Etico Regionale per la Sperimentazione Clinica Della Regione Toscana, Sezione: AREA VASTA CENTRO, n 12113_oss) and the same ethics committee\u00a0granted a waiver of informed consent from study participants.\u00a0that, in keeping with statements by the Italian Regulatory Authorities for retrospective, observational studies ()<u>,<\/u> All methods were carried out in\u00a0accordance\u00a0with relevant guidelines and regulations\/Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1010"}}